In Brief: Genzyme/IG Labs
This article was originally published in The Gray Sheet
Genzyme/IG Labs: Enter agreement in principle under which Genzyme would acquire all publicly held shares of genetic testing services company IG Labs in a tax-free merger worth approximately $21 mil. According to terms of the proposed deal, public stockholders of IG Labs would receive $7 in Genzyme General Division common stock for each IG Labs share. Genzyme's General Division consists of therapeutics, diagnostic products and services, pharmaceuticals and fine chemicals...
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.